Data / Drug companies / Genentech, Inc.
Genentech, Inc.: 88 products in the FDA NDC directory, labeler code 50242
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Genentech, Inc. (labeler code 50242) lists 88 products in the FDA National Drug Code Directory, covering 35 finished drugs by generic name. By type: 74 prescription drugs, 14 drugs for further processing. Its main marketing category is biologics (BLA). The newest product started marketing on October 15, 2026.
The request: Watch Genentech, Inc. (FDA labeler code 50242): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 50242
- Products in commercial distribution
- 88
- Packages
- 130
- Finished drugs by generic name
- 35
- Prescription products
- 74
- Over the counter products
- 0
- Flagged as original packager
- 57 of 57 products that carry the flag
- Started marketing in the last 12 months
- 3
- Products with a marketing end date set
- 3
- Earliest marketing start
- November 13, 1987
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Biologics (BLA) | 56 | 63.6% |
| New drug applications (NDA) | 18 | 20.5% |
| Drugs for further processing | 14 | 15.9% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 74 | 84.1% |
| Drugs for further processing | 14 | 15.9% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Emicizumab | 6 | 1 |
| Tocilizumab | 5 | 4 |
| Baloxavir marboxil | 5 | 2 |
| Mosunetuzumab | 4 | 1 |
| Omalizumab | 4 | 1 |
| Tenecteplase | 3 | 1 |
| Ranibizumab | 3 | 1 |
| Alteplase | 3 | 1 |
| Entrectinib | 3 | 1 |
| Rituximab and hyaluronidase | 2 | 1 |
| Rituximab | 2 | 1 |
| Ado-trastuzumab emtansine | 2 | 1 |
| Glofitamab | 2 | 1 |
| Risdiplam | 2 | 1 |
| Pertuzumab, trastuzumab, and hyaluronidase-zzxf | 2 | 1 |
| Pirfenidone | 2 | 26 |
| Bevacizumab | 2 | 1 |
| Inavolisib | 2 | 1 |
| Atezolizumab | 2 | 1 |
| Polatuzumab vedotin | 2 | 1 |
| Satralizumab | 2 | 1 |
| Trastuzumab | 1 | 4 |
| Vismodegib | 1 | 1 |
| Trastuzumab and hyaluronidase-oysk | 1 | 1 |
| Vemurafenib | 1 | 1 |
| Dornase alfa | 1 | 1 |
| Ocrelizumab and hyaluronidase | 1 | 1 |
| Faricimab | 1 | 1 |
| Crovalimab | 1 | 1 |
| Alectinib hydrochloride | 1 | 1 |
| Cobimetinib | 1 | 1 |
| Obinutuzumab | 1 | 1 |
| Ocrelizumab | 1 | 1 |
| Atezolizumab and hyaluronidase-tqjs | 1 | 1 |
| Pertuzumab | 1 | 1 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 31 | 35.2% |
| Liquid | 11 | 12.5% |
| Injection, powder, lyophilized, for solution | 6 | 6.8% |
| Tablet, film coated | 6 | 6.8% |
| Kit | 5 | 5.7% |
| Injection, solution, concentrate | 5 | 5.7% |
| Capsule | 4 | 4.5% |
| Solution | 4 | 4.5% |
| Injection | 4 | 4.5% |
| Concentrate | 3 | 3.4% |
| Tablet, coated | 2 | 2.3% |
| Granule, for suspension | 2 | 2.3% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| CD20-directed Cytolytic Antibody | 7 |
| Endoglycosidase | 7 |
| Vascular Endothelial Growth Factor Inhibitor | 5 |
| HER2/neu Receptor Antagonist | 5 |
| Kinase Inhibitor | 5 |
| Interleukin-6 Receptor Antagonist | 5 |
| Polymerase Acidic Endonuclease Inhibitor | 5 |
| Anti-IgE | 4 |
| Programmed Death Receptor-1 Blocking Antibody | 3 |
| Bispecific CD20-directed CD3 T Cell Engager | 2 |
| Survival of Motor Neuron 2 Splicing Modifier | 2 |
| Pyridone | 2 |
| Hedgehog Pathway Inhibitor | 1 |
| Recombinant Human Deoxyribonuclease 1 | 1 |
| Complement C5 Inhibitor | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Enspryng | 50242-005 | Injection, solution | Biologics (BLA) | October 15, 2026 |
| Lunsumio Velo | 50242-201 | Injection | Biologics (BLA) | December 19, 2025 |
| Lunsumio Velo | 50242-177 | Injection | Biologics (BLA) | December 19, 2025 |
| Xofluza | 50242-617 | Granule, for suspension | New drug applications (NDA) | May 30, 2025 |
| Xofluza | 50242-599 | Granule, for suspension | New drug applications (NDA) | May 30, 2025 |
| TNKase | 50242-014 | Kit | Biologics (BLA) | February 28, 2025 |
| Evrysdi | 50242-202 | Tablet | New drug applications (NDA) | February 11, 2025 |
| Itovebi | 50242-084 | Tablet, film coated | New drug applications (NDA) | October 14, 2024 |
| Itovebi | 50242-079 | Tablet, film coated | New drug applications (NDA) | October 14, 2024 |
| Ocrevus Zunovo | 50242-554 | Injection, solution | Biologics (BLA) | September 13, 2024 |
| Tecentriq Hybreza | 50242-933 | Injection | Biologics (BLA) | September 12, 2024 |
| Piasky | 50242-115 | Injection, solution | Biologics (BLA) | June 20, 2024 |
| Hemlibra | 50242-927 | Injection, solution | Biologics (BLA) | January 31, 2024 |
| TNKase | 50242-176 | Kit | Biologics (BLA) | January 5, 2024 |
| Rozlytrek | 50242-623 | Pellet | New drug applications (NDA) | October 20, 2023 |
| Xolair | 50242-227 | Injection, solution | Biologics (BLA) | August 18, 2023 |
| Columvi | 50242-127 | Concentrate | Biologics (BLA) | June 15, 2023 |
| Columvi | 50242-125 | Solution, concentrate | Biologics (BLA) | June 15, 2023 |
| Astegolimab | 50242-400 | Liquid | Drugs for further processing | May 16, 2023 |
| Hemlibra | 50242-930 | Injection, solution | Biologics (BLA) | March 16, 2023 |
| Lunsumio | 50242-159 | Concentrate | Biologics (BLA) | December 22, 2022 |
| Lunsumio | 50242-142 | Concentrate | Biologics (BLA) | December 22, 2022 |
| Mosunetuzumab | 50242-243 | Liquid | Drugs for further processing | March 2, 2022 |
| Mosunetuzumab | 50242-242 | Liquid | Drugs for further processing | March 2, 2022 |
| Vabysmo | 50242-096 | Injection, solution | Biologics (BLA) | January 28, 2022 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.